CYTARABINE

Basic Information

Item Value
DrugBank ID DB00987
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 760

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 acute promyelocytic leukemia TxGNN Knowledge Graph
2 therapy related acute myeloid leukemia and myelodysplastic syndrome TxGNN Knowledge Graph
3 acute myeloid leukemia with CEBPA somatic mutations TxGNN Knowledge Graph
4 acute myeloid leukemia with t(8;21)(q22;q22) translocation TxGNN Knowledge Graph
5 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor TxGNN Knowledge Graph
6 leukemia, lymphocytic, susceptibility to TxGNN Knowledge Graph
7 acute myeloblastic leukemia with maturation TxGNN Knowledge Graph
8 precursor T-cell acute lymphoblastic leukemia TxGNN Knowledge Graph
9 unclassified acute myeloid leukemia TxGNN Knowledge Graph
10 acute lymphoblastic/lymphocytic leukemia TxGNN Knowledge Graph
11 inherited acute myeloid leukemia TxGNN Knowledge Graph
12 acute myeloid leukemia with t(9;11)(p22;q23) TxGNN Knowledge Graph
13 acute myeloid leukemia with minimal differentiation TxGNN Knowledge Graph
14 acute lymphoblastic leukemia (disease) TxGNN Knowledge Graph
15 acute myeloid leukemia with t(8;16)(p11;p13) translocation TxGNN Knowledge Graph
16 acute myeloblastic leukemia without maturation TxGNN Knowledge Graph
17 acute myeloid leukemia with t(6;9)(p23;q34) TxGNN Knowledge Graph
18 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) TxGNN Knowledge Graph
19 acute myeloid leukemia with NPM1 somatic mutations TxGNN Knowledge Graph
20 myeloid leukemia TxGNN Knowledge Graph
21 acute promyelocytic leukemia TxGNN Knowledge Graph
22 therapy related acute myeloid leukemia and myelodysplastic syndrome TxGNN Knowledge Graph
23 acute myeloid leukemia with CEBPA somatic mutations TxGNN Knowledge Graph
24 acute myeloid leukemia with t(8;21)(q22;q22) translocation TxGNN Knowledge Graph
25 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor TxGNN Knowledge Graph
26 leukemia, lymphocytic, susceptibility to TxGNN Knowledge Graph
27 acute myeloblastic leukemia with maturation TxGNN Knowledge Graph
28 precursor T-cell acute lymphoblastic leukemia TxGNN Knowledge Graph
29 unclassified acute myeloid leukemia TxGNN Knowledge Graph
30 acute lymphoblastic/lymphocytic leukemia TxGNN Knowledge Graph
31 inherited acute myeloid leukemia TxGNN Knowledge Graph
32 acute myeloid leukemia with t(9;11)(p22;q23) TxGNN Knowledge Graph
33 acute myeloid leukemia with minimal differentiation TxGNN Knowledge Graph
34 acute lymphoblastic leukemia (disease) TxGNN Knowledge Graph
35 acute myeloid leukemia with t(8;16)(p11;p13) translocation TxGNN Knowledge Graph
36 acute myeloblastic leukemia without maturation TxGNN Knowledge Graph
37 acute myeloid leukemia with t(6;9)(p23;q34) TxGNN Knowledge Graph
38 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) TxGNN Knowledge Graph
39 acute myeloid leukemia with NPM1 somatic mutations TxGNN Knowledge Graph
40 myeloid leukemia TxGNN Knowledge Graph
41 acute promyelocytic leukemia TxGNN Knowledge Graph
42 therapy related acute myeloid leukemia and myelodysplastic syndrome TxGNN Knowledge Graph
43 acute myeloid leukemia with CEBPA somatic mutations TxGNN Knowledge Graph
44 acute myeloid leukemia with t(8;21)(q22;q22) translocation TxGNN Knowledge Graph
45 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor TxGNN Knowledge Graph
46 leukemia, lymphocytic, susceptibility to TxGNN Knowledge Graph
47 acute myeloblastic leukemia with maturation TxGNN Knowledge Graph
48 precursor T-cell acute lymphoblastic leukemia TxGNN Knowledge Graph
49 unclassified acute myeloid leukemia TxGNN Knowledge Graph
50 acute lymphoblastic/lymphocytic leukemia TxGNN Knowledge Graph

(Showing top 50 of 760 predictions)

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search